Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

Abstract

This is the first study to compare early relapse switch probability in the period immediately following switch to oral treatment in a population previously stable on injectable therapy. There was no evidence of disease reactivation within the first 6 months of switching to oral therapy.